Cabenuva/Apretude Enrollment and Patient Consent Form



Fax Referral To: 1-855-297-1270

Phone: 1-888-280-1190 Address: 6020 Ave Roberto Sanchez Vilella Carolina, PR 00982

Six Sir	mple Steps to Submitt	ing a Referral	
PATIENT INFORMATION (Patient must of	ion Date:		
Patient Name:			
City, State, ZIP Code:			Gender: Male Female
Primary Phone: Alter	rnate Phone:	Email:	
By providing the phone number(s) and email address above, you prescription(s), account and health care. Standard data rates a Note: Carrier charges may apply. By providing the phone number from CVS Specialty® about your prescription(s), account, and he Specialty Pharmacy will attempt to contact by phone. Designated Patient Contact By signing below, I authorize my Contact, listed by	pply. Message frequency varies. per(s) and email address above, you nealth care. Standard data rates app	are consenting to receive aut ly. Message frequency varies.	omated calls, emails and/or text messages If unable to contact via text or email,
including ability to make decisions on my behalf, extended-release injectable suspension) or Apre liable for any decision(s) made by the Contact or	, for which I will remain liable etude (cabotegravir extende	e, regarding delivery of ed-release injectable su	f Cabenuva (cabotegravir/rilpivirine uspension). CVS Specialty is not
Contact as set forth above: Contact Name:	Relation	ship:	Phone:
		- 1	
Patient's Signature: Patient Authorization			Date:
I hereby authorize CVS Specialty to contact my p my Cabenuva or Apretude prescription medicati scheduled appointment. I understand that my sig will not outreach/contact me and/or my designate circumstances.** I further agree to pay to CVS S without prior outreach to me or my designated of	ion for the sole purpose of a gnature below serves as the ated contact on this form, pr pecialty any required copay	dministration by my properties. Patient Ship Authorization to shipping medicat	escribing provider at my next ation, which means the pharmacy tion except in certain
Patient's Authorization:			Date:
**CVS Specialty may contact patient and/or patient's designee available to Medicare and Medicaid patients because governm required to pay for a prescription in accordance with a Plan, who balance, if any, paid by a Plan. PRESCRIBER INFORMATION	ent payors are excluded from this o	ffering. Copayment, copay or	coinsurance means the amount a member is
Facility Type: Private Practice Outpatie	ent Hospital/Clinic C Othe	ır.	
Prescriber's First Name:			
State License#: DEA#:	Frescriber's Last i	Proctice/Facility	Nemo:
Practice Address (Ship to Address):			
State/ZIP Code:Ph			Number:
Office Contact Name:	Contact's Ph		
INSURANCE INFORMATION Please fax Is the Patient Insured? Yes No Is the Patient Holder's Name: Medical Insurance:	tient enrolled or eligible for I Policy Holder's Telephone:	Medicare/Medicaid? DOB:Re Policy ID:	☐ Yes ☐ No elationship to Patient: Group #:
Prescription Insurance: Gro	P	rescription Plan Teleph	none:
Policy ID: Gro	oup #:	RX BIN #:	RX PCN #:
Check box if patient is enrolled in manufacture			
4 DIAGNOSIS AND CLINICAL INFORM			
	<u>Diagnosis (ICD-10</u>		
B20 Human Immunodeficiency Virus (HIV) Di Other Code: Description			V pre-exposure prophylaxis
Patient Clinical Information:			
Allergies: Has patient previously been treated for HIV? If YES, list all previous medications:	Yes No		kg Height: in cm
List concomitant medications (e.g., anticonvulsa (Rifampin, Rifapentine, Rifabutin), dexamethasor	ants (Carbamazepine, Oxcar		al, Phenytoin), antimycobacterials

NCPDP: 4026325

	enuva/Apretude Enroll Please Complete Patient, Pres					
Patient Name:	ient Name: Pati		t DOB: Patient Phone:			
Patient Address:						
Prescriber Name:	to therapy Continuation of therap	Presci	iber Phone:			
reatment status: [_] New 1	to therapy [] Continuation of therap	by: Date c	or last treatment/	_/		
PRESCRIPTION INFO	PRMATION (to be completed by p	rescribe	only)			
MEDICATION	STRENGTH		DOSE & DIRECTIONS		QUANTITY/REFILLS	
Apretude						
Apretude 600 mg	600 mg/3mL single-dose vial of cabotegravir	into the	Loading dose (Month 1 & Month 2): Inject 3 mL to the muscle at month 1 and month 2, then every 2 onths thereafter		Quantity: 1 dosing kit Refills: <u>1</u>	
Apretude 600 mg	600 mg/3mL single-dose vial of cabotegravir	☐ Maintenance dose (Month 4+): Inject 3 mL into the muscle every 2 months		Quantity: 1 dosing kit Refills:		
Cabenuva						
Option 1: Every-2-Month [Dosing					
Cabenuva 600/900 mg Injection Kit	600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine	Loading dose (Month 1 & Month 2): Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle once monthly for 2 months then maintenance dose as directed		Quantity: 1 dosing kit Refills: <u>1</u>		
Cabenuva 600/900 mg	600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine	☐ Maintenance dose (Month 4+): Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle every 2 months		Quantity: 1 dosing kit Refills:		
Option 2: Every-1-Month [Dosing	•				
Cabenuva 600/900 mg	600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine	Loading dose: Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle on day 1. Follow with maintenance dose in 1 month			Quantity: 1 dosing kit Refills: <u>None</u>	
Cabenuva 400/600 mg	400 mg/2 mL single-dose vial of cabotegravir + 600 mg/2 mL single-dose vial of rilpivirine	Inject 2	tenance dose: mL of cabotegravir and 2 mL o muscle every month	f rilpivirine	Quantity: 1 dosing kit Refills:	
PRESCRIBER SIGNA	ATURE REQUIRED (STAMP S	IGNAT	URE NOT ALLOWED)			
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature:			May Substitute / Product Selection Substitution Permissible Prescriber's Signature:			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates.